TORONTO – Pfizer says it has submitted preliminary trial data to Health Canada for the use of its COVID-19 vaccine in children aged five to 11 years.
In an email to Granthshala.ca, Pfizer Canada confirmed that the company has sent findings about its COVID-19 vaccine in children for review and continues to work with Heath Canada as it aims to have a formal vaccine by mid-October. Submission is to be filed.
There are currently no COVID-19 vaccines approved for use in children under the age of 12 in Canada.
- Newsletter sign-up: Get the COVID-19 brief sent to your inbox
Health Minister Patty Hajdu previously told Granthshala’s Power Play that government health officials are in constant contact with Pfizer regarding vaccine data in children.
“As soon as we receive data from the company, regulators are well positioned to review that data expeditiously,” she said on Tuesday.
The pharmaceutical company announced last week that its vaccine, developed in partnership with German company BioNTech, has been shown to be effective in children aged five to 11 years.
In early trials, Pfizer tested a much lower dose — in a study involving 2,268 kindergarten and elementary school-aged children — that is now one-third of each adult shot given. After their second dose, the company said antibody levels in these children were as high as those of teens and young adults getting the regular-strength shots.
Pfizer submitted its study data to the US Food and Drug Administration on Tuesday and said it expected to apply for emergency authorization of its use for children in the coming weeks.
Meanwhile, Moderna is currently studying the efficacy of its COVID-19 vaccine in primary school-aged children.
Both Pfizer and Moderna are also teaching young children, including those as young as six months old. Results are expected later in the year.
With files from Granthshala.ca author Anthony Vasquez-Pedi